TY - JOUR T1 - ASSESSING THE RELATIONSHIP BETWEEN MONOALLELIC <em>PARK2</em> MUTATIONS AND PARKINSON’S RISK JF - medRxiv DO - 10.1101/2020.06.26.20138172 SP - 2020.06.26.20138172 AU - Steven J Lubbe AU - Bernabe Bustos AU - Jing Hu AU - Dimitri Krainc AU - Theresita Joseph AU - Jason Hehir AU - Manuela Tan AU - Weijia Zhang AU - Valentina Escott-Price AU - Nigel M Williams AU - Cornelis Blauwendraat AU - Andrew B Singleton AU - Huw R Morris AU - for International Parkinson’s Disease Genomics Consortium (IPDGC) Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/28/2020.06.26.20138172.abstract N2 - Biallelic PARK2 (Parkin) mutations cause autosomal recessive Parkinson’s (PD); however, the role of monoallelic PARK2 mutations as a risk factor for PD remains unclear. We investigated the role of single heterozygous PARK2 mutations in three large independent case-control cohorts totalling 10,858 PD cases and 8,328 controls. Overall, after exclusion of biallelic carriers, single PARK2 mutations were more common in PD than controls conferring a &gt;1.5-fold increase in risk of PD (P=0.035), with meta-analysis (19,574 PD cases and 468,488 controls) confirming increased risk (OR=1.65, P=3.69E-07). Carriers were shown to have significantly younger ages at onset compared to non-carriers (NeuroX: 56.4 vs. 61.4 years; Exome: 38.5 vs. 43.1 years). Stratifying by mutation type, we provide preliminary evidence for a more pathogenic risk profile for single PARK2 copy number variant (CNV) carriers compared to single nucleotide variant carriers. Studies that did not assess biallelic PARK2 mutations or consist of predominantly early-onset cases may be biasing these estimates, and removal of these resulted in a loss of association (OR=1.23, P=0.614; n=4). Importantly, when we looked for additional CNVs in 30% of PD cases with apparent monoallellic PARK2 mutations we found that 44% had biallelic mutations suggesting that previous estimates may be influenced by cryptic biallelic mutation status. While this study supports the association of single PARK2 mutations with PD, it highlights confounding effects therefore caution is needed when interpreting current risk estimates. Together, we demonstrate that comprehensive assessment of biallelic mutation status is essential when elucidating PD risk associated with monoallelic PARK2 mutations.Competing Interest StatementH.R.M reports grants from Medical Research Council UK, grants from Wellcome Trust, grants from Parkinson's UK, grants from Ipsen Fund, during the conduct of the study; grants from Motor Neuron Disease Association, grants from Welsh Assembly Government, personal fees from Teva, personal fees from Abbvie, personal fees from Teva, personal fees from UCB, personal fees from Boerhinger-Ingelheim, personal fees from GSK, outside the submitted work. D.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed.Funding StatementPlease see supplementary dataAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As analyses utitlize secondary analyses of suitably anonymized datasets, they do not require ethics committee review. The respective ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent in the original publications for the datasets used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor publicly available datasets, the data are available through application at the relevant sites.%PercentAAOAge at onsetARAutosomal recessivec.coding DNA reference sequenceC1-4Principal component 1 to 4CIConfidence intervalCNVCopy number variantCoeffβ-CoefficientdbGaPDatabase of Genotypes and PhenotypesDNADeoxyribonucleic acidEGAEuropean Genome-phenome ArchiveEOPDEarly-onset Parkinson’sFBXO7F-box protein 7FreqFrequencyI2Proportion of total variation caused by heterogeneityIPDGCInternational Parkinson’s Disease Genomics ConsortiumLRRK2Leucine-rich repeat kinase 2MLPAMultiplex ligation-dependent probe amplificationMRC-HollandMicrobiology Research Centre HollandNNumberNM_*Messenger RNA sequence identifierOMIMOnline Mendelian Inheritance in ManOROdds ratioPP-valuep.protein reference sequencePARK2ParkinPARK7Parkinsonism associated deglycase or DJ-1PDParkinson’sPD-MonoallelicParkinson’s cases harbouring a single heterozygous PARK2 mutationPhetCochran’s Q-statistic test for heterogeneity P-valuePINK1PTEN-Induced putative kinase 1PlogLogistic regression P-valuePPMIParkinson’s Progression Markers InitiativePregLinear regression P-valueReseqResequencingSNCAα-SynucleinSNVSingle nucleotide variantVPS35Vacuolar protein sorting 35, yeast, homolog ofvs.Versus ER -